Analysis of the Relationship between Disease Duration, Comorbidities, and Emotional Disorders and the Level of Disability in Patients with Multiple Sclerosis
DOI:
https://doi.org/10.15225/PNN.2026.15.2.1Keywords
comorbidities, disability, disease duration, EDSS, emotional disorders, multiple sclerosisAbstract
Introduction. Multiple sclerosis (MS) is a chronic disease of the central nervous system that leads to increasing disability and deterioration in patients’ functioning.
Aim. To assess the relationship between disease duration, comorbidities, treatment modification, emotional disorders, and the level of disability in patients with MS.
Material and Methods. A retrospective analysis of medical records of 149 patients treated at the Neurology Outpatient Clinic of the Stanisław Staszic Specialist Hospital in Piła was conducted. The analysis included disease duration, disability level assessed using the Expanded Disability Status Scale (EDSS), treatment, comorbidities, and emotional disorders. Spearman’s rank correlation and the Mann–Whitney U test were applied.
Results. A statistically significant, weak positive relationship was found between disease duration and disability level (r=0.185; p=0.024). Comorbidities were associated with a tendency toward higher EDSS scores, but the difference was not statistically significant (p=0.088). Treatment modifications, most commonly due to insufficient efficacy or adverse effects, were not significantly associated with disability level (p=0.101). Emotional disorders were present in 14.1% of patients, and their association with EDSS was not statistically significant (p=0.154).
Conclusions. Disease duration is significantly associated with the level of disability in patients with MS. Comprehensive and regular monitoring of patients’ health status may support individualized care. (JNNN 2026;15(2):47–54)
References
[1] Trojan G., Nadgrodkiewicz K. Indywidualizacja leczenia stwardnienia rozsianego — opis przypadku. Farmakoter Psychiatr Neurol. 2024;40(1):61–68.
[2] Haki M., Al-Biati H.A., Al-Tameemi Z.S., Ali I.S., Al-Hussaniy H.A. Review of multiple sclerosis: Epidemiology, etiology, pathophysiology, and treatment. Medicine (Baltimore). 2024;103(8):e37297.
[3] Krzystanek E., Bonek R., Rejdak K., Betscher E. Badania diagnostyczne. W: Bonek R. (Red.), Stwardnienie rozsiane. Od chemokin do przeciwciał monoklonalnych. Wyd. Lekarskie PZWL, Warszawa 2019;207–270.
[4] Kułakowska A., Mirowska-Guzel D., Kalinowska A. i wsp. Leczenie modyfikujące przebieg stwardnienia rozsianego. Rekomendacje Sekcji Stwardnienia Rozsianego i Neuroimmunologii Polskiego Towarzystwa Neurologicznego. Pol Przegl Neurol. 2023;19(3):163–189.
[5] Meyer-Moock S., Feng Y.S., Maeurer M., Dippel F.W., Kohlmann T. Systematic literature review and validity evaluation of the Expanded Disability Status Scale (EDSS) and the Multiple Sclerosis Functional Composite (MSFC) in patients with multiple sclerosis. BMC Neurol. 2014;14:58.
[6] Ministerstwo Zdrowia. Chorobowość stwardnienia rozsianego w Polsce. https://analizy.mz.gov.pl/html/zpa_sm/chorobowosc.html.
[7] Orton S.M., Herrera B.M., Yee I.M. et al. Sex ratio of multiple sclerosis in Canada: a longitudinal study. Lancet Neurol. 2006;5(11):932–936.
[8] Kearns P.K.A., Paton M., O’Neill M. et al. Regional variation in the incidence rate and sex ratio of multiple sclerosis in Scotland 2010-2017: findings from the Scottish Multiple Sclerosis Register. J Neurol. 2019;266(10):2376–2386.
[9] Koch-Henriksen N., Sørensen P.S. The changing demographic pattern of multiple sclerosis epidemiology. Lancet Neurol. 2010;9(5):520–532.
[10] Leray E., Yaouanq J., Le Page E. et al. Evidence for a two-stage disability progression in multiple sclerosis. Brain. 2010;133(Pt 7):1900–1913.
[11] Confavreux C., Vukusic S. Natural history of multiple sclerosis: a unifying concept. Brain. 2006;129(Pt 3):606–616.
[12] Lefort M., Vukusic S., Casey R., Edan G., Leray E. Disability Progression in Multiple Sclerosis Patients using Early First-line Treatments. Eur J Neurol. 2022;29(9):2761–2771.
[13] Kapica-Topczewska K., Collin F., Tarasiuk J. et al. Assessment of Disability Progression Independent of Relapse and Brain MRI Activity in Patients with Multiple Sclerosis in Poland. J Clin Med. 2021;10(4):868.
[14] Stanikić M., Salmen A., Chan A. et al. Association of age and disease duration with comorbidities and disability: A study of the Swiss Multiple Sclerosis Registry. Mult Scler Relat Disord. 2022;67:104084.
[15] Manouchehrinia A., Westerlind H., Kingwell E. et al. Age Related Multiple Sclerosis Severity Score: Disability ranked by age. Mult Scler. 2017;23(14):1938–1946.
[16] Salter A., Lancia S., Kowalec K., Fitzgerald K.C., Marrie R.A. Comorbidity and Disease Activity in Multiple Sclerosis. JAMA Neurol. 2024;81(11):1170–1177.
[17] Brieva L., Estruch B.C., Merino J.A.G. et al. Disease modifying therapy switching in relapsing multiple sclerosis: A Delphi consensus of the demyelinating expert group of the Spanish society of neurology. Mult Scler Relat Disord. 2022;63:103805.
[18] Hanna M., Strober L.B. Anxiety and depression in Multiple Sclerosis (MS): Antecedents, consequences, and differential impact on well-being and quality of life. Mult Scler Relat Disord. 2020;44:102261.
[19] Bejer A., Ziemba J. Quality of life of patients with multiple sclerosis and degree of motor disability — preliminary report. Med Og Nauk Zdr. 2015;21(4):402–407.
[20] Berrigan L.I., Fisk J.D., Patten S.B. et al. Health-related quality of life in multiple sclerosis: Direct and indirect effects of comorbidity. Neurology. 2016;86(15):1417–1424.
[21] Furmańska J., Rzepa T.N., Koziarska D., Rutkowska E., Bulsa M. Stereotypes vs. Reality: shame and coping strategies applied by healthy subjects and multiple sclerosis patients — preliminary research. Adv Psychiatry Neurol. 2020;29(1):11–24.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2026 Anna Żdanowicz, Julianna Pieczul, Maciej Gawrysiak, Małgorzata Wiszniewska

This work is licensed under a Creative Commons Attribution-NoDerivatives 4.0 International License.
Stats
Number of views and downloads: 8
Number of citations: 0